fda glp-1 compounding enforcement news Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers FDA to Restrict Ingredients Used

At the same time, increased affordability drives higher patient uptake, leading to a surge in demand for delivery devices

In turn, new and existing telehealth companies like Hims, Ro, and Noom situated themselves as middlemen, funneling the supply of compounded medications to customers and reaping huge profits

Tell your doctor's office: "Please request a peer-to-peer review for my denied GLP-1 prior authorization."[9] File a formal appeal using the OAC template The Obesity Action Coalition provides free sample appeal letters and a step-by-step guide for GLP-1 denials.[10] Submit the appeal with updated documentation addressing the exact denial reason: new labs, updated BMI, specialist letters, or evidence of failed prior interventions

There are also exclusivity issues for Wegovy and Ozempic in Brazil, China, and Canada